



I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Box Sequence, P. O. Box 2327, Arlington, VA 22202, on the date below:

November 1, 2002

ate

RECEIVED

NOV 0 8 2002

TECH CENTER 1600/2900

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Ralph et al.

Serial No.: 09/660,568

Filed: September 11, 2000

For: DIAGNOSIS OF DISEASE STATE USING MRNA PROFILES IN PERIPHERAL LEUKOCYTES

Group Art Unit: 1635

Examiner: McGarry, Sean

Atty. Dkt. No.: UROC:014USD1

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE DISCLOSURES

BOX SEQUENCE

Commissioner for Patents Washington, DC 20231

Commissioner:

This paper is submitted in response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence Disclosures mailed October 2, 2002, for which the one-month date for response is November 2, 2002. A Statement as Required Under 37 C.F.R. § 1.825(a) and (b) and Statement as Required Under 37 C.F.R. § 1.821(g) has been included herewith, including a computer readable form.

It is believed that no fee is due. However, should any fees be due for any reason related to these documents, the Commissioner is authorized to withdraw the appropriate fee under 37 C.F.R. §§ 1.16 to 1.21 from Fulbright & Jaworski L.L.P. Account No.: 50-1212/UROC:014USD1.

Respectfully submitted,

Gina N. Shishima Reg. No. 45,104

Attorney for Applicant

FULBRIGHT & JAWORSKI L.L.P. 600 Congress Avenue, Suite 2400 Austin, Texas 78701 (512) 536-3081 (512) 536-4598 (facsimile)

Date:

November 1, 2002